BTIGwill host its first Obesity Health Forum on Wednesday, May 8, 2024. Industry-leading biotechnology firms, digital health companies with a focus on treating obesity and policymakers will be participating in the firm's virtual event which will include thematic panels and fireside chats. The forum will be hosted by:
Justin Zelin, BTIG Biotechnology Analyst
David Larsen, CFA, BTIG Digital Health Analyst
Julian Harrison, BTIG Biotechnology Analyst
Isaac Boltansky, BTIG Directory of Policy Research
"The development and delivery of effective obesity care has brought a shift to healthcare with broad reaching implications for every sector," said Justin Zelin, BTIG Biotechnology Analyst. "Our event will provide a forum for BTIG's institutional investor clients to explore emerging innovations, discuss latest trends and see what's on the horizon."
More than 19 public and private healthcare companies will be participating in the event. Panel discussion topics will include:
Obesity management with coaching, eating, and lifestyle management
GLP-1s are great but how do we pay for them?
How Employers View GLP-1s, Obesity Management, and the ROI for Employees
Bringing Scale and Leverage to the GLP-1 Market
Fireside Chat with the Office of Congressman Brad Wenstrup (R-OH)
The Latest Developments in Obesity Treatment
CB1 Axis Therapies of Obesity
Emerging Therapeutics Panel
The conference is being produced by BTIG's Corporate Access program which hosts client events across the consumer, energy and infrastructure, financials, healthcare, real estate and technology sectors. To access BTIG insights, contact a firm representative or log in to www.btigresearch.com.
About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. The firm's core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...
Product: Kalihim (Philippine Bread Roll)
Issue: Food - Allergen - Egg
Distribution: British Columbia
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform.
Panda Health...